Phase 3 N=216 Maintaining Nonsmoking
Nicotine Dependence
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 12 — 22; 20; 29; 20 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=44 Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
Chronic Graft Versus Host Disease
Primary: Maximum Tolerated Dose of Ofatumumab — 1000 mg
N/A N=23 Clinical Study to Assess the Performance of the Dialyzer With Endexo™
Kidney Failure, Chronic
Primary: Performance of the Dialyzer With Endexo by Measuring Its in Vivo Ultrafiltration Coefficient — 16.36 mL/hr/mmHg
N/A N=30 iLux Treatment for Meibomian Gland Dysfunction (MGD)
Evaporative Dry Eye
Primary: Change From Baseline in Meibomian Gland Secretion (MGS) Total Score — 12.3; 14.5 score on a scale — p=<0.0001
Phase 2 N=159 Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Recurrent Prostate Carcinoma · Stage IV Prostate Cancer AJCC v7
Primary: Confirmed Prostate-specific Antigen (PSA) Response Rate — 46; 55 Participants — p=0.27
Phase 2 N=29 Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) in Study Participants — 46 percentage of participants
Phase 2 N=172 PI-88 in Hepatocellular Carcinoma After Hepatectomy
Carcinoma, Hepatocellular
Primary: Tumour Non-recurrence Rate — 32; 40; 35 Participants — p=0.072
N/A N=250 Evaluation of PCLs Using Three EUS-FNA Needles
Pancreatic Cystic Lesions
Primary: Volume of Aspirated Cyst Fluid as a Function of Estimated Maximal Volume — 78; 74; 73 percentage of cyst volume aspirated — p=0.84
N/A N=346 Effectiveness of Abdominal Binder Use During Colonoscopy
Performance and Tolerance of Colonoscopy
Primary: Mean Cecal Intubation Time — 240; 250 sec — p=0.388
N/A N=60 The Effect of Lumbar Stabilization Exercise and Gait Training on Lower Back Muscles- Electromyographic(EMG) Analysis
Low Back Pain
Primary: Low Back Pain at Resting Status — 30.58; 37.50; 30.00; 41.92 score on a scale
Phase 2 N=47 Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Hepatocellular Carcinoma · Liver Cancer
Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months
Phase 2 N=200 A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine
Respiratory Disorders
Primary: Number of Subjects Reported With Each Solicited Local Adverse Event (AE) (Any and Grade 3) Within Each Vaccination Schedule — 64; 64; 2; 1 Participants
Phase 2 N=65 Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
Lymphoma
Primary: Overall Survival — 32; 33 Participants
Phase 4 N=350 Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care
Hepatitis C · Substance Use Disorders · Substance Abuse, Intravenous
Primary: SVR 12 — 24; 15; 47; 1 Participants
N/A N=842 Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: the TESTsmART Trial AIM 1
Malaria · Febrile Illness
Primary: Number of Participants That Purchase an mRDT (Malaria Rapid Diagnostic Test) — 205; 195; 207; 211 Participants — p=0.01